Caribou Biosciences Files 8-K

TL;DR

CRBU filed an 8-K, likely containing important updates. Check for details.

AI Summary

On January 12, 2025, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This 8-K filing indicates that Caribou Biosciences is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a change in risk.

Key Players & Entities

• Caribou Biosciences, Inc. (company) — Registrant
• 2929 7th Street, Suite 105 Berkeley, California 94710 (location) — Principal Executive Offices
• January 12, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global

Filing Documents

• crbu-20250112.htm (8-K) — 30KB
• crbu-20250113xexx991.htm (EX-99.1) — 33KB
• img25401123_0a.jpg (GRAPHIC) — 51KB
• 0001619856-25-000006.txt ( ) — 271KB
• crbu-20250112.xsd (EX-101.SCH) — 2KB
• crbu-20250112_lab.xml (EX-101.LAB) — 23KB
• crbu-20250112_pre.xml (EX-101.PRE) — 13KB
• crbu-20250112_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 12, 2025, Caribou Biosciences, Inc. ("Caribou" or the "Company") issued a press release highlighting 2024 clinical events and corporate accomplishments and providing an outlook of anticipated 2025 clinical milestones. A copy of the press release is furnished herewith as Exhibit 99.1 and also is incorporated by reference into this Item 7.01. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Forward-looking statements

Forward-looking statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements related to Caribou's strategy, plans, and objectives, and expectations regarding its clinical and preclinical development programs, including its plans to present or provide (i) ANTLER phase 1 clinical trial data in the first half of 2025 from both the additional second line and prior CD19 relapsed large B cell lymphoma patients and the timing and commencement of an ANTLER pivotal phase 3 clinical trial; (ii) dose escalation data in the first half of 2025 from the ongoing CaMMouflage phase 1 clinical trial for CB-011 in patients with relapsed or refractory multiple myeloma; (iii) updates on dose escalation from the AMpLify Phase 1 clinical trial for CB-012; and (iv) updates from the GALLOP phase 1 clinical trial for CB-010 in patients with lupus nephritis and extrarenal lupus; as well as its expected funding runway of cash, cash equivalents, and marketable securities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of Caribou's current and fu

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Caribou Biosciences, Inc. on January 1 2, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Caribou Biosciences, Inc. Date: January 13, 2025 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR